Gartner Faces Short Squeeze Risk or Value Trap as Legal Deadline Looms and Growth Falters

The immediate catalyst is a securities class action lawsuit filed against Gartner. The complaint alleges the company and its executives made false statements by repeatedly claiming it could achieve 12-16% contract value growth rates in a "normal" economy, a promise now contradicted by its actual performance. The lawsuit, which has a May 18, 2026 deadline for potential lead plaintiffs, centers on the stark disconnect between those optimistic projections and the reality of a sharp growth decline.

This legal event arrives against a backdrop of severe stock underperformance. The shares are down 39.6% over the last 120 days and have fallen 38.4% year-to-date, trading near their 52-week low of $139.18. The market's verdict on Gartner's growth story has been brutal and prolonged. The lawsuit, therefore, is not a new shock but a formal accusation that validates deep-seated skepticism already baked into the price.

Recent analyst action underscores the pressure. Just last week, Wells Fargo's analyst lowered the price target from $150 to $140 while maintaining an underweight rating, a move that coincided with a nearly 1% drop in share price. The rationale points to tangible headwinds: macroeconomic volatility and a declining contract value growth that has stalled. This sets up a clear tension. The lawsuit alleges past deception, while the analyst downgrade highlights present and future risks. The stock's collapse suggests the market has already priced in significant disappointment. The catalyst now is whether this legal action can spark a short squeeze among those betting against the stock, or if the underlying business deterioration makes the setup a classic value trap.

The Financial Reality: Growth and Profitability Under Pressure

The lawsuit's core allegation hinges on a broken promise. The company and its executives are accused of touting a 12-16% contract value growth rate as achievable in a "normal" economy. The financial reality, however, tells a starkly different story. In the fourth quarter of 2025, the company's global contract value grew just 1% on an FX-neutral basis. For the full year, revenue rose only 3% on an FX-neutral basis, far below the promised range. This isn't just a slowdown; it's a fundamental failure to deliver on stated growth targets.

The pressure is equally clear on the bottom line. Adjusted earnings per share for the quarter were $3.94, down 28% year-over-year. Full-year net income plunged 42%. The company's own guidance for 2026, which calls for at least 2% FX-neutral revenue growth, suggests this is a new, lower baseline. CFO Craig Safian explicitly stated the company now views a 23.5% EBITDA margin as the new baseline, indicating a margin reset due to "selected investments" and persistent demand headwinds.

This profitability strain was partially masked last year by aggressive capital return. In 2025, Gartner repurchased $2 billion of its own stock, reducing the share count by 8%. That buyback provided a direct, artificial boost to EPS. Without it, the underlying earnings decline would have been even more pronounced. The company has now refreshed its share repurchase authorization, signaling a continued commitment to returning capital, but that strategy cannot compensate for a stagnating top line.

The bottom line is one of clear business pressure. The alleged growth promises were never met, and the financials show a company grappling with a tougher selling environment. The stock's collapse reflects this erosion in fundamental health. The lawsuit is a legal catalyst, but the financials provide the substance of the case.

The Valuation and Catalyst Landscape: What to Watch

The stock's valuation is a direct reflection of extreme pessimism. Trading at $155.42, it is down 39.6% over the last 120 days and has fallen 38.4% year-to-date. The rolling annual return stands at a staggering -64.5%, and the share price is just over a third of its 52-week high of $451.73. This isn't just a correction; it's a deep discount that prices in severe disappointment. The key question is whether this discount is a buying opportunity or a value trap.

The immediate catalyst is the May 18, 2026 deadline for potential lead plaintiffs in the securities class action. This date could trigger a formal complaint, leading to heightened scrutiny and potentially a short squeeze among investors who have bet against the stock. The lawsuit alleges the company's false promises about 12-16% contract value growth were a material misrepresentation. If the case gains momentum, it could create a narrative-driven pop, regardless of near-term fundamentals.

The next major data point is the Q1 2026 earnings report. Investors must watch for any signs of stabilization in the core metric at the heart of the lawsuit: contract value growth. The company's own guidance for 2026 calls for at least 2% FX-neutral revenue growth, a significant reset from its past promises. Management's forward guidance and any commentary on the trajectory of CV growth will be critical. A failure to show acceleration, as it had promised, would confirm the lawsuit's thesis and likely keep pressure on the stock. Conversely, a surprise beat or a more optimistic tone could spark a relief rally.

The bottom line is a high-stakes setup. The valuation discount is extreme, but the underlying business faces tangible headwinds. The May 18 deadline is a binary event that could create volatility. The Q1 report will provide the first real test of whether the company's new, lower growth baseline is holding. For now, the stock remains a speculative bet on a legal catalyst or a fundamental turnaround, with little middle ground.